AC Immune SA
NASDAQ:ACIU
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.29
5
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ACIU stock under the Base Case scenario is 9.58 USD. Compared to the current market price of 3.38 USD, AC Immune SA is Undervalued by 65%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
AC Immune SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ACIU cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
AC Immune SA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
AC Immune SA
Balance Sheet Decomposition
AC Immune SA
Current Assets | 187.6m |
Cash & Short-Term Investments | 157.9m |
Receivables | 26.2m |
Other Current Assets | 3.4m |
Non-Current Assets | 56.7m |
Long-Term Investments | 415k |
PP&E | 5.8m |
Intangibles | 50.4m |
Current Liabilities | 101m |
Accounts Payable | 1.4m |
Accrued Liabilities | 12.9m |
Other Current Liabilities | 86.7m |
Non-Current Liabilities | 13.1m |
Long-Term Debt | 2.4m |
Other Non-Current Liabilities | 10.7m |
Earnings Waterfall
AC Immune SA
Revenue
|
41m
CHF
|
Operating Expenses
|
-78.3m
CHF
|
Operating Income
|
-37.3m
CHF
|
Other Expenses
|
-2.6m
CHF
|
Net Income
|
-39.9m
CHF
|
Free Cash Flow Analysis
AC Immune SA
CHF | |
Free Cash Flow | CHF |
ACIU Profitability Score
Profitability Due Diligence
AC Immune SA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
AC Immune SA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
ACIU Solvency Score
Solvency Due Diligence
AC Immune SA's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
AC Immune SA's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACIU Price Targets Summary
AC Immune SA
According to Wall Street analysts, the average 1-year price target for ACIU is 10.46 USD with a low forecast of 8.08 USD and a high forecast of 16.8 USD.
Dividends
Current shareholder yield for ACIU is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Contact
IPO
Employees
Officers
The intrinsic value of one ACIU stock under the Base Case scenario is 9.58 USD.
Compared to the current market price of 3.38 USD, AC Immune SA is Undervalued by 65%.